A critical appraisal of chronic kidney disease mineral and bone disorders clinical practice guidelines using the AGREE II instrument

Imagem de Miniatura
Arquivos
art_SEKERCIOGLU_A_critical_appraisal_of_chronic_kidney_disease_mineral_2017.PDF (513.67 KB)
Citações na Scopus
28
Tipo de produção
article
Data de publicação
2017
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER
Autores
SEKERCIOGLU, Nigar
AL-KHALIFAH, Reem
EWUSIE, Joycelyne Efua
THABANE, Lehana
BUSSE, Jason W.
AKHTAR-DANESH, Noori
IORIO, Alfonso
ISAYAMA, Tetsuya
MARTINEZ, Juan Pablo Diaz
Citação
INTERNATIONAL UROLOGY AND NEPHROLOGY, v.49, n.2, p.273-284, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Patients with chronic kidney disease mineral and bone disorders (CKD-MBD) suffer high rates of morbidity and mortality, in particular related to bone and cardiovascular outcomes. The management of CKD-MBD remains challenging. The objective of this systematic survey is to critically appraise clinical practice guidelines (CPGs) addressing CKD-MBD. Data sources included MEDLINE, EMBASE, the National Guideline Clearinghouse, Guideline International Network and Turning Research into Practice up to May 2016. Teams of two reviewers, independently and in duplicate, screened titles and abstracts and potentially eligible full text reports to determine eligibility and subsequently appraised the guidelines using the Advancing Guideline Development, Reporting and Evaluation in Health Care instrument II (AGREE). Sixteen CPGs published from 2003 to 2015 addressing the diagnosis and management of CKD-MBD in adult patients (11 English, two Spanish, one Italian, one Portuguese and one Slovak) proved eligible. The National Institute for Health and Care Excellence guideline performed best with respect to AGREE II criteria; only three other CPGs warranted high scores on all domains. All other guidelines received scores of under 60% on one or more domains. Major discrepancies in recommendations were not, however, present, and we found no association between quality of CPGs which was not associated with resulting recommendations. Most guidelines assessing CKD-MBD suffer from serious shortcomings using AGREE criteria although limitations with respect to AGREE criteria do not necessarily lead to inappropriate recommendations.
Palavras-chave
Chronic kidney disease, Advancing guideline development, Reporting and evaluation in health care instrument, Clinical practice guidelines, Mineral and bone disorder
URI
https://observatorio.fm.usp.br/handle/OPI/19038
Referências
  1. AGREE II, 2010, PREV MED, V51, P421, DOI [10.1016/j.ypmed.2010.08.005, DOI 10.1016/J.YPMED.2010.08.005]
  2. Barriocanal AM, 2016, J VASC SURG, V63, P1091, DOI 10.1016/j.jvs.2015.12.040
  3. Brosseau L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095369
  4. Brosseau L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0082986
  5. Carvalho Aluízio Barbosa, 2012, J. Bras. Nefrol., V34, P199, DOI 10.1590/S0101-28002012000200015
  6. Cernaro V, 2016, INT J NEPHROL RENOV, V9, P11, DOI 10.2147/IJNRD.S78040
  7. Chadban S, 2010, NEPHROLOGY, V15, pS43, DOI 10.1111/j.1440-1797.2010.01233.x
  8. Cluzeau FA, 1999, INT J QUAL HEALTH C, V11, P21, DOI 10.1093/intqhc/11.1.21
  9. Cortes-Sanabria L, 2013, PERITON DIALYSIS INT, V33, P679, DOI 10.3747/pdi.2011.00274
  10. Centre for Clinical Practice at N. National Institute for Health and Clinical Excellence: Guidance, 2013, HYP CHRON KIDN DIS M
  11. Cunningham J, 2011, CLIN J AM SOC NEPHRO, V6, P913, DOI 10.2215/CJN.06040710
  12. Djulbegovic B, 2014, BMJ-BRIT MED J, V312, P1293, DOI 10.1001/JAMA.2014.10713
  13. Arenas MD, 2007, NEPHROL DIAL TRANSPL, V22, P1639, DOI 10.1093/ndt/gfl840
  14. Elder Grahame, 2006, Nephrology (Carlton), V11 Suppl 1, pS230, DOI 10.1111/j.1440-1797.2006.00508.x
  15. Field B, 2014, IMPLEMENT SCI, V9, DOI 10.1186/s13012-014-0172-2
  16. Fukagawa M, 2013, THER APHER DIAL, V17, P247, DOI 10.1111/1744-9987.12058
  17. Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD
  18. Guyatt GH, 2013, J CLIN EPIDEMIOL, V66, P158, DOI 10.1016/j.jclinepi.2012.01.012
  19. Hawley Carmel, 2006, Nephrology (Carlton), V11 Suppl 1, pS198, DOI 10.1111/j.1440-1797.2006.00643.x
  20. Hazlewood GS, 2014, J CLIN EPIDEMIOL, V67, P1274, DOI 10.1016/j.jclinepi.2014.07.005
  21. Jamal SA, 2013, LANCET, V382, P1268, DOI 10.1016/S0140-6736(13)60897-1
  22. Jha V, 2013, LANCET, V382, P260, DOI 10.1016/S0140-6736(13)60687-X
  23. Jindal Kailash, 2006, J Am Soc Nephrol, V17, pS1
  24. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group, 2009, KIDNEY INT S113, V76, pS1
  25. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group, 2012, KIDNEY INT S, V2013, P1
  26. Laliberte F, 2009, J MANAGE CARE PHARM, V15, P312
  27. Levey AS, 2007, KIDNEY INT, V72, P247, DOI 10.1038/sj.ki.5002343
  28. Levin A, 2008, CAN MED ASSOC J, V179, P1154, DOI 10.1503/cmaj.080351
  29. Manns BJ, 2010, AM J KIDNEY DIS, V55, P800, DOI 10.1053/j.ajkd.2010.02.339
  30. Mazzaferro S, 2007, G Ital Nefrol, V24 Suppl 37, pS107
  31. Meyer C, 2012, CANNT J J ACITN, V22, P36
  32. Meyer Caitlin, 2012, CANNT J, V22, P33
  33. Moe SM, 2006, EUR J CLIN INVEST, V36, P51, DOI 10.1111/j.1365-2362.2006.01665.x
  34. National Institutes of Health NIoDaDaKD, 2015, 2015 USRDS ANN DAT R
  35. National Kidney Foundation, 2003, AM J KIDNEY DIS S, V42, pS1, DOI 10.1016/S0272-6386(03)00905-3
  36. Parra EG, 2008, NEFROLOGIA, V28, P1
  37. Patel L, 2015, CLIN J AM SOC NEPHRO, V14
  38. Pitt SC, 2009, SURG CLIN N AM, V89, P1227, DOI 10.1016/j.suc.2009.06.011
  39. Prados-Garrido MD, 2011, DIAL TRASPL, V32, P108
  40. Rebic D, 2015, RENAL FAILURE, V19, P1
  41. Sanchez-Perales C, 2015, NEFROLOGIA, V35, P157, DOI 10.1016/j.nefro.2015.05.017
  42. Smith CAM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137180
  43. Smith DH, 2004, J AM SOC NEPHROL, V15, P1300, DOI 10.1097/01.ASN.0000125670.64996.BB
  44. Stedon S, 2015, CLIN PRACTICE GUIDEL
  45. Suja A, 2012, J Pharm Bioallied Sci, V4, P107, DOI 10.4103/0975-7406.94810
  46. Vlayen J, 2005, INT J QUAL HEALTH C, V17, P235, DOI 10.1093/intqhc/mzi027
  47. Watine J, 2006, CLIN CHEM, V52, P65, DOI 10.1373/clinchem.2005.056952
  48. Wetmore JB, 2009, NAT CLIN PRACT NEPHR, V5, P24, DOI 10.1038/ncpneph0977
  49. Wilkieson Trevor J, 2015, Can J Kidney Health Dis, V2, P29, DOI 10.1186/s40697-015-0065-6
  50. Yan JP, 2013, J EVAL CLIN PRACT, V19, P626, DOI 10.1111/j.1365-2753.2012.01873.x
  51. Zarnke KB, 2000, CAN J CARDIOL, V16, P1094
  52. Zhai CJ, 2015, INT UROL NEPHROL, V47, P527, DOI 10.1007/s11255-014-0876-x
  53. [Anonymous], 2014, HYPERPHOSPHATAEMIA C
  54. [Anonymous], 2009, AKTUALITY NEFROLOGII, V15, P121
  55. 2002, NEPHROLOGY DIALYSIS, V17, P17

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - ODS/03